Jovita Marcinkeviciene

Executive Director, Cardiovascular and Metabolism at Novartis Biomedical Research

Speaker

Jovita joined Novartis Institute for Biomedical Research in 2009 as the Head of the Biochemistry Unit in the Cardiovascular and Metabolism Disease Area. Since 2017 she has been responsible for the Metabolic disease and Obesity strategy and emerging portfolio. Prior to Novartis Jovita was a group leader of the molecular pharmacology core group at Bristol-Myers Squibb (BMS), where she made important contributions to discovery of Onglyza^TM (DPP4 inhibitor), as well as advancing a number of exploratory efforts in metabolic disease indications. Jovita’s expertise is in mechanistic enzymology and biochemistry of metabolic pathways which she successfully applied to multiple drug discovery programs.

Jovita obtained her PhD from the Institute of Biochemistry in Vilnius (Lithuania) where she studied the metabolism of nitro compounds by the adrenodoxin reductase/adrenodoxin enzymatic system. After a fellowship at the University of Lund (Sweden) and postdoctoral fellowship at Albert Einstein College of Medicine in NY she joined Dupont Pharmaceuticals where she stayed until acquisition by BMS. Jovita has authored more than fifty scientific publications.